Neurovascular changes in acute, sub-acute and chronic mouse models of parkinson's disease

Current Neurovascular Research

Volumn 11, Issue 1, 2014, Pages 48-61

  Sarkar, Sumit ^a   Raymick, James ^b   Mann, Dushyant ^c   Bowyer, John F ^a   Hanig, Joseph P ^d   Schmued, Larry C ^a   Paule, Merle G ^a   Chigurupati, Srinivasulu ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Wayne State Univ School of Medicine ^*

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Blood vessel; Blood brain barrier; Endothelial cells; FT gel; GFAP; MPTP; NeuN; Parkinson's disease; TH

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GELATIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; BRAIN BLOOD VESSEL; CAUDATE PUTAMEN; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ENDOTHELIUM CELL; GLIOSIS; IMMUNOHISTOCHEMISTRY; LONG TERM EXPOSURE; MALE; MICROVASCULATURE; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NONHUMAN; NUTRIENT AVAILABILITY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CEREBRAL VENTRICLES; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; PHOSPHOPYRUVATE HYDRATASE; STILBAMIDINES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84898739105     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202610666131124234506     Document Type: Article

References (80)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68(5): 384-6.
2. Hornykiewicz O. A brief history of levodopa. J Neurol 2010; 257(Suppl 2): S249-52.
3. Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr 1961; 73: 787-8.
4. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30(5): 194-202.
5. Bjorklund A, Dunnett SB. Fifty years of dopamine research. Trends Neurosci 2007; 30(5): 185-7.
6. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 2006; (70): 9-15.
7. Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology 2007; 68(2): 159-60.
8. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7(1): 41-53.
9. Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res 2003; 314(1): 119-29.
10. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57(2): 173-85.
11. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57(2): 178-201.
12. Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 2000; 100(4): 395-402.
13. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011; 25(1): 5-13.
14. Barcia C, Emborg ME, Hirsch EC, Herrero MT. Blood vessels and parkinsonism. Front Biosci 2004; 9: 277-82.
15. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 2007; 16(3): 285-99.
16. Muramatsu Y, Kurosaki R, Watanabe H, et al. Cerebral alterations in a MPTP-mouse model of Parkinson's disease - an immunocytochemical study. J Neural Transm 2003; 110(10): 1129-44.
17. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15(7 Pt 1): 4738-47.
18. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119(1): 182-92.
19. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspec Med 2012; 2(1): a009381.
20. Reynolds AD, Glanzer JG, Kadiu I, et al. Nitrated alpha- synucleinactivated microglial profiling for Parkinson's disease. J Neurochem 2008; 104(6): 1504-25.
21. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 2003; 17(8): 944-6.
22. Dauphin F, MacKenzie ET. Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Pharmacol Ther 1995; 67(3): 385-417.
23. Bian GL, Wei LC, Shi M, Wang YQ, Cao R, Chen LW. Fluoro- Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice. Brain Res 2007; 1150: 55-61.
24. Chen LW, Hu HJ, Liu HL, Yung KK, Chan YS. Identification of brain-derived neurotrophic factor in nestin-expressing astroglial cells in the neostriatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice. Neuroscience 2004; 126(4): 941-53.
25. Chen LW, Wei LC, Qiu Y, et al. Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice. Are the striatal astrocytes regionally activated after systemic MPTP administration? Brain Res 2002; 925(1): 9-17.
26. Chen LW, Zhang JP, Kwok-Yan Shum D, Chan YS. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated C57/Bl mice. J Comp Neurol 2006; 497(6): 898-909.
27. Sarkar S, Raymick J, Paule MG, Schmued L. In situ demonstration of Fluoro-Turquoise conjugated gelatin for visualizing brain vasculature and endothelial cells and their characterization in normal and kainic acid exposed animals. J Neurosci Methods 2013; 219(2): 276-84.
28. Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005; 1035(1): 24-31.
29. Chigurupati S, Son TG, Hyun DH, et al. Lifelong running reduces oxidative stress and degenerative changes in the testes of mice. J Endocrinol 2008; 199(2): 333-41.
30. Paxinos G, Franklin KBJ. The Mouse Brain in Sterotaxic Coordinates: Compact Second Edition. 2003; Second Edition.
31. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984; 224(4656): 1451-3.
32. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311(5985): 467-9.
33. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989; 10(3): 171-83.
34. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.
35. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001; 106(3): 589-601.
36. Guan J, Pavlovic D, Dalkie N, et al. Vascular degeneration in Parkinson's disease. Brain Pathol 2013; 23(2): 154-64.
37. Intaglietta M, Johnson PC, Winslow RM. Microvascular and tissue oxygen distribution. Cardiovasc Res 1996; 32(4): 632-43.
38. Sagare AP, Bell RD, Zlokovic BV. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(10).
39. Spielmeyer W. The significance of local factors for the electivity in central nervous system disease processs. Medicine (Baltimore) 1931; 10: 243-56.
40. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996; 92(2): 197-201.
41. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27(5): 457-64.
42. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994; 15(3): 329-35.
43. Ohnishi T, Hoshi H, Nagamachi S, et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. J Nucl Med 1995; 36(7): 1163-9.
44. Leenders KL, Wolfson L, Gibbs JM, et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 1985; 108 (Pt 1): 171-91.
45. Kawabata K, Tachibana H, Sugita M. Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol 1991; 4(4): 194-203.
46. Varma AR, Talbot PR, Snowden JS, Lloyd JJ, Testa HJ, Neary D. A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J Neurol 1997; 244(6): 349-59.
47. De Jong GI, Farkas E, Stienstra CM, et al. Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. Neuroscience 1999; 91(1): 203-10.
48. Pappas BA, de la Torre JC, Davidson CM, Keyes MT, Fortin T. Chronic reduction of cerebral blood flow in the adult rat: lateemerging CA1 cell loss and memory dysfunction. Brain Res 1996; 708(1-2): 50-8.
49. Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia 1996; 7(5): 239-45.
50. Rapoport SI, Horwitz B, Grady CL, Haxby JV, DeCarli C, Schapiro MB. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. Adv Exp Med Biol 1991; 291: 231-48.
51. Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB. Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res 1990; 27(4): 561-8.
52. Sasaki M, Ichiya Y, Hosokawa S, et al. Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia. Ann Nucl Med 1992; 6(4): 241-6.
53. Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38(5): 797-802.
54. Harik SI. Changes in the glucose transporter of brain capillaries. Can J Physiol Pharmacol 1992; 70 Suppl: S113-7.
55. Horwood N, Davies DC. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Arch 1994; 425(1): 69-72.
56. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 1997; 18(5): 469-74.
57. Rektor I, Goldemund D, Sheardova K, Rektorova I, Michalkova Z, Dufek M. Vascular pathology in patients with idiopathic Parkinson's disease. Parkinsonism Relat Disord 2009; 15(1): 24-9.
58. Al-Bachari S, Parkes L, Vidyasagar R, et al. Clinical phenotypespecific differences in cerebral haemodynamics in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84(11): e2.
59. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999; 56(1): 98-102.
60. Inzelberg R, Korczyn AD. Parkinsonism in adult-onset GM2 gangliosidosis. Mov Disord 1994; 9(3): 375-7.
61. Sawada H, Udaka F, Kameyama M, et al. SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992; 55(10): 960-3.
62. Korczyn AD. The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005; 229-230: 3-6.
63. Zarow C, Barron E, Chui HC, Perlmutter LS. Vascular basement membrane pathology and Alzheimer's disease. Ann N Y Acad Sci 1997; 826: 147-60.
64. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990; 24(5): 677-86.
65. Kelleher RJ, Soiza RL. Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis 2013; 3(4): 197-226.
66. Thomas T, McLendon C, Sutton ET, Thomas G. Cerebrovascular endothelial dysfunction mediated by beta-amyloid. Neuroreport 1997; 8(6): 1387-91.
67. Karlhuber GM, Bauer HC, Eckl PM. Cytotoxic and genotoxic effects of 4-hydroxynonenal in cerebral endothelial cells. Mutat Res 1997; 381(2): 209-16.
68. Gorman AM, McGowan A, O'Neill C, Cotter T. Oxidative stress and apoptosis in neurodegeneration. J Neurol Sci 1996; 139 Suppl: 45-52.
69. Gsell W, Strein I, Krause U, Riederer P. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease - a comparative review. J Neural Transm Suppl 1997; 51: 145-59.
70. Owen AD, Schapira AH, Jenner P, Marsden CD. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. J Neural Transm Suppl 1997; 51: 167-73.
71. Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68(3): 409-27.
72. Fernandez-Klett F, Offenhauser N, Dirnagl U, Priller J, Lindauer U. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci U S A 2010; 107(51): 22290-5.
73. de Jong LW, Wang Y, White LR, Yu B, van Buchem MA, Launer LJ. Ventral striatal volume is associated with cognitive decline in older people: a population based MR-study. Neurobiol Aging 2012; 33(2): 424 e1-10.
74. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990; 27(4): 373-85.
75. Abe Y, Yamamoto T, Soeda T, et al. Diabetic striatal disease: clinical presentation, neuroimaging, and pathology. Intern Med 2009; 48(13): 1135-41.
76. Iseki E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. Neuropathology 2004; 24(1): 72-8.
77. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci 2013; 14(11): 21525-50.
78. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999; 353(9157): 981-2.
79. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485(7399): 512-6.
80. Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000; 879(1-2): 115-21.